Lowering blood pressure in a mobile stroke unit for very early brain bleeding
Compares blood pressure treatment in mobile stroke units with standard ambulance care in brain bleeding.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have just had a stroke caused by bleeding in the brain. Treatment to lower blood pressure starts within 3 hours of symptom onset.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute stroke, with less than 3 hours from symptom onset (last known normal) to enrollment. Systolic blood pressure from 150 mmHg to 220 mmHg.
Main reasons for not taking part
- Glasgow Coma Scale (GCS) score of 5 or lower
- Conditions that make intensive blood pressure lowering unsafe, such as severe arterial stenosis or high-grade stenotic valvular heart disease
- Malignant disease or other serious illness with a life expectancy of less than 3 months
- Currently taking part in another interventional randomized clinical trial
Read by machine on 9 November 2026.
Where in China
- Xuanwu HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xuanwu Hospital, Beijing
- Trial code
- NCT07665827
- Record updated
- 24 June 2026
- Original description
MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.Read full original descriptionShow less
Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial
MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.
Inclusion: History and physical/neurological examination consistent with acute stroke; Age ≥18 years; Time from symptom onset to enrollment <3 hours (onset defined as last known normal); Systolic blood pressure ≥150 mmHg and ≤220 mmHg; Pre-stroke modified Rankin Scale (mRS) score ≤2; Informed consent obtained from the subject or a legally authorized representative.
Exclusion: Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease; Malignant disease or other serious primary illness with a life expectancy of <3 months; Glasgow Coma Scale (GCS) score ≤5; Current participation in another interventional randomized clinical trial.